Nektar (NKTR) Reports Q4 Earnings: What Key Metrics Have to Say

Core Insights - Nektar Therapeutics reported a revenue of $29.18 million for the quarter ended December 2024, reflecting a year-over-year increase of 22.1% [1] - The earnings per share (EPS) was$ 0.15, a significant improvement from - $0.22 in the same quarter last year, resulting in an EPS surprise of +215.38% compared to the consensus estimate of -$ 0.13 [1] - The reported revenue fell short of the Zacks Consensus Estimate of $39.02 million by 25.23% [1] Revenue Breakdown - Product sales reached$ 12.87 million, exceeding the average estimate of $9.76 million from eight analysts, marking a year-over-year increase of 134.8% [4] - Non-cash royalty revenue related to future royalties was$ 16.24 million, slightly above the estimated $15.15 million, but showed a decline of 10.1% compared to the previous year [4] - License, collaboration, and other revenue was only$ 0.06 million, significantly below the average estimate of $28.26 million from four analysts, representing a year-over-year decrease of 81.5% [4] Stock Performance - Nektar's shares have returned +23.5% over the past month, contrasting with a -8.2% change in the Zacks S&P 500 composite [3] - The stock currently holds a Zacks Rank 2 (Buy), suggesting potential for outperformance in the near term [3]